Minority Representation in studies cited as references in National Comprehensive Cancer Network (NCCN) Guidelines for Prostate Cancer.

Zhong Zheng,Lang Qu,Heyue Du,Chao Y. Wang,Xi Cao,Yujun Xiong,Barbara Yim,Shweta Gupta
DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.e18511
IF: 45.3
2022-06-01
Journal of Clinical Oncology
Abstract:e18511 Background: Prostate cancer (PC) has a higher incidence, higher lifetime risk, higher risk of progression and lower overall 5-year survival in African American (AA) men compared to Caucasian men. Historically AA men have been under-represented in clinical studies that may prevent some AA men with PC to receive appropriate therapies. We aim to estimate the AA representation in studies cited in national guidelines for PC. Methods: We retrospectively reviewed all listed references in the National Comprehensive Cancer network (NCCN) Prostate cancer guidelines version 2.2021. All cited papers were reviewed for patient level data on racial or ethnic distribution in the study population. Subgroup analysis was performed by subheadings in the guidelines for Black/African American (AA) representation in each topic of discussion. Duplicate studies in the same section were excluded. Results: A total 836 references were screened of which 167 (20%) reported patient race/ethnicity distribution. Overall, 2,711,194 patients were included in reported studies of which 2,263,936 (83.5%) were Caucasian, 12.6% AA and 3.9% others. A total 26 studies reported 20% or more AA of which 14 were under 500 patients only. While 72 studies included over 1000 patients, only 9 of them had over 20% AA patients. Only 1 study (72 patients) out of 12 for systemic therapy in castration-naïve PC reported ethnicities. For Castration resistant PC, ethnicity data was available for 152 patients (3 of 10 studies), 771 patients (2 of 11 studies) and 1200 patients (1 of 4 studies) in abiraterone, enzalutamide and apalutamide studies respectively with 47.4%, 9.2% and 5.7% AA respectively. Olaparib, rucaparib, pembrolizumab and bisphosphonates studies reported 1.4%, 6.3%, 7% and 5.7% AA respectively. Further subgroup analysis is presented in Table. Conclusions: Race/ethnicity data is not reported widely in clinical studies. The overall AA representation remains very low which is also an underestimation since about 80% studies did not report patient ethnicities. Clinical investigators should be encouraged to report racial representation in studies which will help personalize cancer care for African Americans who are at high risk.[Table: see text]
oncology
What problem does this paper attempt to address?